Caliper's Shares Drop Despite Patent Allowance | GenomeWeb
Shares in Caliper Life Sciences fell nearly 10 percent for the five-day trading period ended Tuesday, despite the firm’s announcement last week that it had received a key patent allowance (see related article). The firm also reaffirmed its full-year revenue guidance of $137 million to $143 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.